z-logo
open-access-imgOpen Access
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Author(s) -
Susanggie,
Curtis Cooper,
Michael S. Saag,
Kimberly Workowski,
Peter Ruane,
William Towner,
Kristen Marks,
Anne F. Luetkemeyer,
Rachel Baden,
Paul E. Sax,
Edward Gane,
Jorge SantanaBagur,
Luisa M. Stamm,
Jenny C. Yang,
Polina German,
Hadas DvorySobol,
Liyun Ni,
Phillip S. Pang,
John G. McHutchison,
Catherine Stedman,
Javier O Morales-Ramirez,
Norbert Bräu,
Dushyantha Jayaweera,
Amy E. Colson,
Pablo Tebas,
David Wong,
Douglas T. Dieterich,
Mark Sulkowski
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1501315
Subject(s) - medicine , ledipasvir , sofosbuvir , adverse effect , efavirenz , gastroenterology , hepatitis c virus , emtricitabine , regimen , hepatitis c , raltegravir , cirrhosis , viral load , virology , human immunodeficiency virus (hiv) , ribavirin , virus , antiretroviral therapy
Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom